Cargando…
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam
OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incrementa...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871542/ https://www.ncbi.nlm.nih.gov/pubmed/27192051 http://dx.doi.org/10.1371/journal.pone.0155699 |
_version_ | 1782432614772113408 |
---|---|
author | Nguyen, Thi-Phuong-Lan Wright, E. Pamela Nguyen, Thanh-Trung Schuiling-Veninga, C. C. M. Bijlsma, M. J. Nguyen, Thi-Bach-Yen Postma, M. J. |
author_facet | Nguyen, Thi-Phuong-Lan Wright, E. Pamela Nguyen, Thanh-Trung Schuiling-Veninga, C. C. M. Bijlsma, M. J. Nguyen, Thi-Bach-Yen Postma, M. J. |
author_sort | Nguyen, Thi-Phuong-Lan |
collection | PubMed |
description | OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied. RESULTS: Cost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered. CONCLUSION: From a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval. |
format | Online Article Text |
id | pubmed-4871542 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-48715422016-05-31 Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam Nguyen, Thi-Phuong-Lan Wright, E. Pamela Nguyen, Thanh-Trung Schuiling-Veninga, C. C. M. Bijlsma, M. J. Nguyen, Thi-Bach-Yen Postma, M. J. PLoS One Research Article OBJECTIVE: To inform development of guidelines for hypertension management in Vietnam, we evaluated the cost-effectiveness of different strategies on screening for hypertension in preventing cardiovascular disease (CVD). METHODS: A decision tree was combined with a Markov model to measure incremental cost-effectiveness of different approaches to hypertension screening. Values used as input parameters for the model were taken from different sources. Various screening intervals (one-off, annually, biannually) and starting ages to screen (35, 45 or 55 years) and coverage of treatment were analysed. We ran both a ten-year and a lifetime horizon. Input parameters for the models were extracted from local and regional data. Probabilistic sensitivity analysis was used to evaluate parameter uncertainty. A threshold of three times GDP per capita was applied. RESULTS: Cost per quality adjusted life year (QALY) gained varied in different screening scenarios. In a ten-year horizon, the cost-effectiveness of screening for hypertension ranged from cost saving to Int$ 758,695 per QALY gained. For screening of men starting at 55 years, all screening scenarios gave a high probability of being cost-effective. For screening of females starting at 55 years, the probability of favourable cost-effectiveness was 90% with one-off screening. In a lifetime horizon, cost per QALY gained was lower than the threshold of Int$ 15,883 in all screening scenarios among males. Similar results were found in females when starting screening at 55 years. Starting screening in females at 45 years had a high probability of being cost-effective if screening biannually was combined with increasing coverage of treatment by 20% or even if sole biannual screening was considered. CONCLUSION: From a health economic perspective, integrating screening for hypertension into routine medical examination and related coverage by health insurance could be recommended. Screening for hypertension has a high probability of being cost-effective in preventing CVD. An adequate screening strategy can best be selected based on age, sex and screening interval. Public Library of Science 2016-05-18 /pmc/articles/PMC4871542/ /pubmed/27192051 http://dx.doi.org/10.1371/journal.pone.0155699 Text en © 2016 Nguyen et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Nguyen, Thi-Phuong-Lan Wright, E. Pamela Nguyen, Thanh-Trung Schuiling-Veninga, C. C. M. Bijlsma, M. J. Nguyen, Thi-Bach-Yen Postma, M. J. Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title | Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title_full | Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title_fullStr | Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title_full_unstemmed | Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title_short | Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam |
title_sort | cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in vietnam |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871542/ https://www.ncbi.nlm.nih.gov/pubmed/27192051 http://dx.doi.org/10.1371/journal.pone.0155699 |
work_keys_str_mv | AT nguyenthiphuonglan costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT wrightepamela costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT nguyenthanhtrung costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT schuilingveningaccm costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT bijlsmamj costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT nguyenthibachyen costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam AT postmamj costeffectivenessanalysisofscreeningforandmanagingidentifiedhypertensionforcardiovasculardiseasepreventioninvietnam |